Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (27183)	1/5/1999 10:37:00 AM
From: Henry Niman	Read Replies (3) \| Respond to of 32384

LGND is reviewed this morning on Online Investor : iionline.com

To: Arthur Radley who wrote (27183)	1/6/1999 6:05:00 PM
From: Henry Niman	Respond to of 32384

Individual Investor online report also covered by NewsTraders.com: January 05, 1999 11:27 Ligand Pharm Is Niche Biotech Nearing Profitability (LGND) - Report (NewsTraders.com)-- The outlook for Ligand Pharmaceuticals (LGND) is "especially bright" as the company appears close to turning a profit in 1999, according to a report* on Individual Investor Online. Report Highlights: - The biotech company is well funded by a "who's who" of corporate partners. - The company concentrates on using its biotechnology prowess to tackle cancer, metabolic and skin diseases. - Ligand has two marketable products and three more new drug applications (NDAs) expected for 1999. - Medical Technology Stock Letter editor Jim McCamant thinks Ligand shares are worth a purchase for under $16, and has set a $30 price target on the stock, which is significantly above a recent price of $11.63.